Guangzhou Baiyunshan Board Approves Subsidiary Share Placement of Up to RMB 6 Billion

• Guangzhou Baiyunshan Pharmaceutical Holdings' board on November 9, 2026, backed subsidiary GP Corp.'s proposed private placement to raise up to RMB 6 billion.
• The placement would issue up to 1,734,104,046 shares at no less than RMB 3.46 each.
• Proceeds would repay up to RMB 5.5 billion in bank borrowings, with up to RMB 500 million allocated to working capital.
• The transaction would dilute the parent's stake from 90.92% to no less than 53.23%, preserving control.
• Shareholders will vote on a proposed mandate covering the issuance, valid for up to 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261109-12406281), on November 09, 2026, and is solely responsible for the information contained therein.